이 에피소드에 관해
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
영어
미국
과거 에피소드 검색
FDA CDER Small Business and Industry Assistance (SBIA) Chronicles의 과거 에피소드를 검색하세요.
이 팟캐스트의 다른 에피소드
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
면책 조항: 이 페이지에 포함된 팟캐스트와 작품은 U.S. Food and Drug Administration, Center for Drug Evaluation and Research에서 가져온 것입니다. 이 팟캐스트는 소유자의 재산이며 Listen Notes, Inc.와 제휴하거나 보증하지 않습니다.
